|Study Type:||Phase Ib|
|Stage:||Primary analysis complete|
|Study Start Date:||NA|
|Study Made Public:||NA|
A Phase Ib clinical trial to compare the safety, tolerability, and immunogenicity of an HIV-1 adenoviral vector boost administered intramuscularly, intradermally, or subcutaneously after an HIV-1 DNA plasmid vaccine prime administered intramuscularly to healthy adenovirus type 5 seropositive HIV-1-uninfected adults
HVTN 069 is a Phase Ib clinical trial to evaluate the safety and immunogenicity of a VRC-HIVDNA009-00-VP (DNA) prime / VRC-HIV ADV014-00-VP (Ad5) boost, where VRC-HIV ADV014-00-VP is administered via different routes.
Sign in to see full information about this study and to download study data.
ProductsProduct info coming soon!
No integrated data is available for this study.
No non-integrated data is available for this study.